View More Recent Stories

Jan 31, 2025 03:26AM JMP Securities Starts Kalvista Pharmaceuticals Inc (KALV) at Market Outperform
Jan 21, 2025 07:01AM KalVista Pharmaceuticals (KALV) Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
Jan 7, 2025 05:32AM TD Cowen Starts Kalvista Pharmaceuticals Inc (KALV) at Buy
Dec 18, 2024 06:33AM BofA Securities Starts Kalvista Pharmaceuticals Inc (KALV) at Buy
Dec 16, 2024 07:01AM KalVista Pharmaceuticals (KALV) Appoints Jeb Ledell as COO
Dec 6, 2024 06:46AM H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
Dec 5, 2024 06:35AM KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 2c
Nov 26, 2024 07:00AM KalVista Pharmaceuticals (KALV) Appoints Laurence Reid to its Board
Nov 5, 2024 07:13AM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Needham
Nov 4, 2024 07:06AM KalVista Pharmaceuticals (KALV) Prices 5.5M Share Offering at $10/sh
Nov 4, 2024 07:04AM KalVista Pharmaceuticals (KALV) Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
Oct 28, 2024 06:31AM KalVista Pharmaceuticals (KALV) Presents New Sebetralstat Data
Oct 7, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
Oct 4, 2024 12:30PM KalVista Pharmaceuticals (KALV) Presents Sebetralstat Data
Sep 30, 2024 06:30AM KalVista Pharmaceuticals (KALV) Submits Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
Sep 27, 2024 07:04AM Jones Trading Starts Kalvista Pharmaceuticals Inc (KALV) at Buy
Sep 10, 2024 06:30AM KalVista (KALV) Appoints Brian Piekos as CFO
Sep 6, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
Sep 6, 2024 06:35AM Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
Sep 6, 2024 06:30AM KalVista Pharmaceuticals (KALV) Presents Sebetralstat Data
Sep 5, 2024 06:31AM KalVista Pharmaceuticals (KALV) Tops Q1 EPS by 3c
Sep 3, 2024 06:31AM KalVista Pharmaceuticals (KALV) Announces FDA Acceptance of NDA for Sebetralstat
Aug 15, 2024 06:32AM KalVista Pharmaceuticals (KALV) Announces Validation of Marketing Authorization Application by the EMA for Sebetralstat
Jul 15, 2024 08:27AM H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
Jul 11, 2024 04:52PM KalVista Pharmaceuticals (KALV) Files $300M Mixed Shelf
Jun 27, 2024 06:31AM KalVista Pharmaceuticals (KALV) Initiates KONFIDENT-KID Trial
Jun 18, 2024 06:31AM KalVista Pharmaceuticals (KALV) Submits NDA to FDA for Sebetralstat
View More Recent Stories